Skip to main content
Fig. 2 | Annals of General Psychiatry

Fig. 2

From: Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Fig. 2

Anticholinergic agent use tolerability outcome—Base case estimates of Risperidone ISM versus comparator treatments. AOM aripiprazole monohydrate once-monthly, CI confidence interval, PP paliperidone palmitate

Back to article page

Annals of General Psychiatry

ISSN: 1744-859X